SPIEGELMAN DANIEL K 4

What Happened Daniel K. Spiegelman, a director of Maze Therapeutics, received a grant/award of a derivative covering 18,000 shares reported at $0.00 on June 8, 2026. The filing classifies this as an award/acquisition (derivative), not an open-market purchase or sale, so no shares were sold and no cash changed hands at the time of the report.

Key Details

• Transaction date: June 8, 2026; Form 4 filed June 10, 2026 (appears timely).
• Instrument: Derivative award (option/award) covering 18,000 shares; reported price $0.00.
• Vesting/ exercisability: The option shall vest and be fully exercisable on the earlier of the issuer's 2027 annual stockholders meeting or June 8, 2027, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in this Form 4.
• No 10b5‑1 plan, tax‑withholding, or sale noted in the filing.

Context This is an equity award that vests in the future and does not represent an immediate market purchase or sale. Such director grants are common as compensation and do not by themselves indicate a purchase signal; they create potential future equity exposure if the recipient remains with the company through the vesting date.